<SEC-DOCUMENT>0001104659-21-124695.txt : 20211129
<SEC-HEADER>0001104659-21-124695.hdr.sgml : 20211129
<ACCEPTANCE-DATETIME>20211008170059
<PRIVATE-TO-PUBLIC>
ACCESSION NUMBER:		0001104659-21-124695
CONFORMED SUBMISSION TYPE:	CORRESP
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20211008

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Entrada Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001689375
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				813983399
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		CORRESP

	BUSINESS ADDRESS:	
		STREET 1:		6 TIDE STREET
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02210
		BUSINESS PHONE:		857-305-1825

	MAIL ADDRESS:	
		STREET 1:		6 TIDE STREET
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02210

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CycloPorters, Inc.
		DATE OF NAME CHANGE:	20161104
</SEC-HEADER>
<DOCUMENT>
<TYPE>CORRESP
<SEQUENCE>1
<FILENAME>filename1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

                           <P STYLE="margin: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="vertical-align: top">
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 80%"><IMG SRC="tm2123090d8img_001.jpg" ALT=""><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 20%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Goodwin Procter <FONT STYLE="font-variant: small-caps">llp<BR>
  </FONT>100 Northern Avenue<BR>
  Boston, MA 02210</FONT><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
                 <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">goodwinlaw.com</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">+1
617 570 1000</FONT></P>

</TD></TR>
</TABLE>


<P STYLE="color: #848A8E; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="color: #848A8E; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">October 8, 2021</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>VIA EDGAR </U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">United States Securities and Exchange Commission</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Division of Corporation Finance</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Office of Life Sciences</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">100 F Street, N.E.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Washington, D.C. 20549</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Attention: Margaret Schwartz, Celeste Murphy, Al Pavot and Jeanne Bennett</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: bold 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="padding-left: 10pt; text-indent: -10pt; width: 6%">&nbsp;</TD>
  <TD STYLE="padding-left: 10pt; text-indent: -10pt; width: 3%">Re:</TD>
  <TD STYLE="text-align: left">Entrada Therapeutics, Inc.<BR>
Amendment No. 1 to Draft Registration Statement on Form S-1<BR>
Submitted September 15, 2021<BR>
File No. 377-05320</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dear Ladies and Gentlemen:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On behalf of our client, Entrada
Therapeutics, Inc. (the &#8220;<B>Company</B>&#8221;), we are responding to the comments from the Staff (the &#8220;<B>Staff</B>&#8221;)
of the Securities and Exchange Commission (the &#8220;<B>Commission</B>&#8221;) relating to the Company&#8217;s confidential Amendment
No. 1 to Draft Registration Statement on Form S-1 contained in the Staff&#8217;s letter dated September 28, 2021 (the &#8220;<B>Comment
Letter</B>&#8221;). The Company is concurrently filing a Registration Statement on Form S-1 (&#8220;<B>Registration Statement</B>&#8221;),
which includes changes to reflect responses to the Staff&#8217;s comments and other updates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Set forth below are the Company&#8217;s
responses to the Staff&#8217;s comments in the Comment Letter. The responses and information below are based on information provided to
us by the Company. For convenience, the Staff&#8217;s comments are repeated below in italics, followed by the Company&#8217;s response
to the comments as well as a summary of the responsive actions taken. We have included page numbers to refer to the location in the Registration
Statement submitted herewith where the revised language addressing a particular comment appears. Capitalized terms used but not defined
herein are used herein as defined in the Registration Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Amendment No. 1 to Draft Registration Statement on Form S-1, Submitted
September 15, 2021 Prospectus Summary, page 1</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 5.45pt"></TD><TD STYLE="width: 35.35pt">1.</TD><TD STYLE="text-align: justify"><I>We note your response to our prior comment number 1. To state that your EEV
therapeutic candidates are efficient with respect to pharmacological effect and specific with respect to the engagement or involvement
with a desired intracellular target of interest implies that your product candidates are effective. Please remove these statements and
all similar statements as this determination is solely within the authority of the FDA and comparable regulatory
bodies.</I></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 9.15pt 0pt 40.8pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="text-transform: uppercase"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="text-transform: uppercase"><B><I></I></B></FONT></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="text-transform: uppercase"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 0in"><FONT STYLE="text-transform: uppercase"><B>Response:
</B></FONT>The Company respectfully advises the Staff that it has revised the statement on page 1 and elsewhere throughout the Registration
Statement in response to the Staff&#8217;s comment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Business, page 112</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 5.45pt"></TD><TD STYLE="width: 35.35pt">2.</TD><TD STYLE="text-align: justify"><I>We note your response to our prior comment number 7. Comparisons to other available
treatments require head-to-head trials. Given these are not head-to-head trials, please remove these statements.</I></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 0in"><FONT STYLE="text-transform: uppercase"><B>Response:
</B></FONT>The Company respectfully advises the Staff that, as discussed with the Staff, it has not removed the disclosure in the Registration
Statement in response to this comment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="padding-left: 10pt; text-indent: -10pt; width: 50%">Sincerely,</TD>
  <TD STYLE="padding-left: 10pt; text-indent: -10pt; width: 50%">&nbsp;</TD></TR>

<TR STYLE="vertical-align: top">
  <TD STYLE="padding-left: 10pt; text-indent: -10pt">&nbsp;</TD>
  <TD STYLE="padding-left: 10pt; text-indent: -10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
  <TD STYLE="border-bottom: Black 1pt solid; padding-left: 10pt; text-indent: -10pt">/s/ Sarah Ashfaq</TD>
  <TD STYLE="padding-left: 10pt; text-indent: -10pt">&nbsp;</TD></TR>

<TR STYLE="vertical-align: top">
  <TD STYLE="padding-left: 10pt; text-indent: -10pt">Sarah Ashfaq &nbsp; </TD>
  <TD STYLE="padding-left: 10pt; text-indent: -10pt">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="padding-left: 10pt; text-indent: -10pt; width: 6%">cc:</TD>
  <TD STYLE="text-align: left">Dipal Doshi, <I>Entrada Therapeutics, Inc.<BR>
</I>Arthur R. McGivern, <I>Goodwin Procter LLP <BR>
</I>Tara Fisher, <I>Ropes &amp; Gray LLP</I></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 296.5pt">&nbsp;</P>



<P STYLE="margin: 0pt"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>tm2123090d8img_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2123090d8img_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  ] /(# 2(  A$! Q$!_\0
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M DN+BY801OMV(.3QGK^->D:=H]AI<'EVMLD8(Y.,D_4US_P];=I%R?\ IO\
M^RBNINIQ;6TL[ E8T+$#T S71A815)3:U./,,15J5Y4V]$]C#U7PAINI$R+'
M]GF/.^/C/U'2N</A_2-!S+K6HK)@Y6&/@L/IUJGJ_CR_N]T=DHMHO[PY<_CV
MKCIY))Y#)+(SN>K,<DURU:E"4KQC=GJ8/!8MPM4GRQ[=?OZ'K?A7Q!8:LUQ:
MV%F;>*W (Z?,#GM^%=17FGPP_P"/W4?]Q/YFO2Z[\/)RIIL\?,*,:.(E".V@
M5A>(O%ND^&85?4)R)&&4A0;G;Z#T]S6X37A_AFP7X@>/K^_U0F6VA)D\K/!&
M<(OTQ_*MCB.B7XTZ:9L-IET(L_>#@G\O_KUW&@>)--\26IN-.G\P*0'1AAT)
M]13+RR\.VULMI>0Z?#"RX6.4*H(]@:B\,Z9H6DP3P:(\#(\ADD,4@<@GH"<]
M/2@";Q!XHTOPU;";4)]I;[D:C+O]!7$_\+ITWSL?V9<B+/WMZYQ]/_KUSMA9
MCQ_\4+W^T&9K.V+MY><?NT8*J_CD$_C7KW_"/Z1]C^R_V;:^1MV^7Y0QB@"+
M0/$^E^)+4SZ=<;]OWXV&'3ZBM"\O+>PM)+JZF2&",9=W. !7B]Y:'P#\4;-;
M!F6SNF0^7G_EF[;64^N",C\*T_B[?W5UK&E>'H7VI,%E8=F9F*+GZ8/YT :=
M]\9-(@N#':V=S<H#CS"0@/TZUM>'/B-HOB*=;9'>VNVX6*; WG_9/?\ 2M'0
MO"&D:'I\=M!:1.X4;Y70%G/<D_TK@_BGX4L].LXM?TV-;6=)E641C:&ST;CH
M0?YT >E:[JJ:)HEUJ3QF5+=-Y13@GG']:\__ .%U6'_0)N/^_H_PK1U#59-:
M^#$U_,<RRVF'/JROM)_,5'\*;&TN/!2O-;12/]HD&YD!/:@"[H/Q/T/6KE+5
MS)9W#G"";&UCZ!A_6M+Q=XN3PE:6]S-927$4SF,E' VG&1V[\_E7+?$_P?IX
MT*76K*W2WNK8J9/+&T2*2%Y'KR.:;$)O&/P:/G R7ELC%&/5FB/'XE>/QH ]
M%TN_CU72[6_A_P!7<1+*H/;(SBN5E^(UC%XR_P"$>-M(6\];?S]PV[CCM]3B
MLOX9>((U\!7(N'XTLR%L_P!S!<?^S#\*\PDT^_FT6;Q<78.=1VDCJ&/S;OSP
M* /H^^O8["PN+R7B*")I7^BC)K!\(>+T\70W4\-E);Q0,J;G<-N)!)QQVX_.
ML'Q_XDCE^&L%S V&U18U4#L"-S?R(_&MOX>:1_8_@RQC9-LTZ_:)/JW(_P#'
M<#\* &^$O','BR[NX(;22 VRAB7<'.21Z>U5=:^(]AH7B?\ L:[MI0H*;[@,
M-JA@#G'MFN3^#/\ R%]9_P"N2?\ H1K*\>Z;+K'Q3FT^!E66=(U0MTSY>1_*
M@#W2.198U=&#*PR".01ZUQ^F_$*VO_&;^&Q92K*L\T/G%QC,88DXQWVUSOPR
M\62Q2MX7U8F.YA)6W,G7CK&?<=JPO#7_ "72;_K_ +W_ -!EH ]THHHJA!7S
MXK^]?0=> +IUPC;9T:(^C#!KSLPM:-SZ#(G%>TOY?J>D_#@YT:Z_Z^/_ &45
MU&I1M+IMU&@RSPLH'J<&O,-"UVYT!3'  \+-N=&[GI7;67C+3+F+=-(;=QU5
M_P"E+#8FDZ?(W9G+CL)65=U8JZ;.-TSP1J5\P:X7[-%ZMRQ_"LCQ)I":-JS6
MD<C.H0-ENO-=GJWCZ.+='IL6]NGF/T_ 5P>H7UQJ5V]S=/OE;@FN:K[&*Y8:
MON>O@IXRI4]I5TCV.M^&(Q>:C_N)_,UZ57G?PUMI4>^N&0B-@JJQ'4\UZ)7H
MX7^$CP\U:>+E;R$(R*\.M+F?X9^/KH74+MIUSD!E'6,G*D>XZ$5[E5#5=%T_
M6K;[/J%K'/'U 8<@^H/:N@\\X/Q/J7@7Q-!;W=_JI/D*VQ(BP;G&1C'7BJ/P
M4Y76R,[=T."?^!UT*?"CPPDWF?9YB,YV&4XKK-.TNRTFV%O8VT<$0_A1<4 >
M-W4EQ\./B1/?O SZ==LY!4?>C<[B![J<?E[UZ+_PL7PQ]C^T?VI'C&=FT[OI
MCUK>U+2;'5K4VU];1SQ'^%QG'TKE/^%4>&//\S[/-C.=GFG% '$6;W/Q%^)$
M.HI Z:=9LAR1]U$.X ^Y)_7VK;^+>B7;36/B&S5F-J!')M&2@#;E;Z9)_,5Z
M1INE66DVJVUC;1P1#^%!C/UJT\:2H4=0RD8((R#0!Q6A?$W0M2T^-[RZ2SN@
MH\R.0'&?8^E<=X_\81^+&MO#^A(]RK2AG=5^^W0 >W.<UVU_\,/#-]<&8V;0
ML>2(7*C\JU=#\(:+X>RUA9JDA&#(WS-^9H P=:TDZ'\(;G3206@M '(Z%BP+
M?J361\-/%&B:1X16UO\ 48H)Q.[;&SG!QCM7HVJ:;;ZOID]A= F"==K@'!QG
M-<E_PJ?PO_SPG_[_ !H YKXA>.[/6=._L+1"UT]PZB1T4X(!R%7U.0*[OP5H
M3Z%X2L["X \[:7E'HS')'X=/PI^B^"]"T&3S;*Q43#I*YW,/H3708XH ^<M7
MEN?"6J>)-!B!6"[Q&OLFX,I_[Y)'XUZG%X4S\)_[%,?[]K3S<=_-^_\ ^A8%
M:NM>!M%U[54U*^@=KA55<JY (!R,CO728^7% 'SCI$MUXIN?#WAJ0$P6TKC_
M ( S;F_( U]&H@1 J@!0, #L*YS2/ ^B:+JSZG90.MRP89+D@;CDX':NDH \
M>^#/_(8UG_KDG_H1I=5_Y+S:_P"]%_Z*KT+P_P"#]*\-3SS:='(KS@!]SEN
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# __9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
